What is Pluri?
Pluri Inc. operates at the forefront of biotechnology, focusing on the development and scaling of proprietary cell expansion platforms. These technologies are designed for diverse applications across healthcare, food production, and agriculture. The company's core innovation lies in its ability to grow and manufacture biological cells for use in regenerative medicine, sustainable food solutions, and other advanced biotechnological advancements, often pursued through strategic partnerships and dedicated research initiatives.
How much funding has Pluri raised?
Pluri has raised a total of $10M across 2 funding rounds:
Other Financing Round
$6.5M
Other Financing Round
$3.5M
Other Financing Round (2025): $6.5M, investors not publicly disclosed
Other Financing Round (2025): $3.5M led by Merchant Adventure Investment Advisors
Key Investors in Pluri
Merchant Adventure Investment Advisors
Merchant Adventure Investment Advisors is an investment firm that focuses on knowledge-based companies creating new products and services. Their framework emphasizes management competency, growth opportunities, franchise quality, and valuation, with a global investment scope.
What's next for Pluri?
The substantial enterprise-level funding and recent strategic investment indicate Pluri is poised for significant expansion and further research and development. This capital injection will likely accelerate the commercialization of its cell-based technologies, potentially enabling the company to scale its operations, forge new strategic alliances, and solidify its market position in the rapidly evolving biotechnology sector. Future growth may involve expanding its application areas or enhancing its manufacturing capabilities.
See full Pluri company page
